targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000041880
|
EFO_0000616
|
NCT04123366
|
Recruiting
| 2 |
2019-11-18
| null | null | null | null |
Phase II+
| 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT04123366
|
Recruiting
| 2 |
2019-11-18
| null | null | null | null |
Phase II+
| 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT04123366
|
Recruiting
| 2 |
2019-11-18
| null | null | null | null |
Phase II+
| 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT04123366
|
Recruiting
| 2 |
2019-11-18
| null | null | null | null |
Phase II+
| 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT04123366
|
Recruiting
| 2 |
2019-11-18
| null | null | null | null |
Phase II+
| 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT04123366
|
Recruiting
| 2 |
2019-11-18
| null | null | null | null |
Phase II+
| 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT04123366
|
Recruiting
| 2 |
2019-11-18
| null | null | null | null |
Phase II+
| 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT04123366
|
Recruiting
| 2 |
2019-11-18
| null | null | null | null |
Phase II+
| 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT04123366
|
Recruiting
| 2 |
2019-11-18
| null | null | null | null |
Phase II+
| 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03239015
|
Recruiting
| 2 |
2017-01-01
| null | null | null | null |
Phase II+
| 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03239015
|
Recruiting
| 2 |
2017-01-01
| null | null | null | null |
Phase II+
| 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03239015
|
Recruiting
| 2 |
2017-01-01
| null | null | null | null |
Phase II+
| 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03239015
|
Recruiting
| 2 |
2017-01-01
| null | null | null | null |
Phase II+
| 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03239015
|
Recruiting
| 2 |
2017-01-01
| null | null | null | null |
Phase II+
| 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03239015
|
Recruiting
| 2 |
2017-01-01
| null | null | null | null |
Phase II+
| 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03239015
|
Recruiting
| 2 |
2017-01-01
| null | null | null | null |
Phase II+
| 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03239015
|
Recruiting
| 2 |
2017-01-01
| null | null | null | null |
Phase II+
| 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03239015
|
Recruiting
| 2 |
2017-01-01
| null | null | null | null |
Phase II+
| 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00782574
|
Active, not recruiting
| 1 |
2008-11-12
| null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00782574
|
Active, not recruiting
| 1 |
2008-11-12
| null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00782574
|
Active, not recruiting
| 1 |
2008-11-12
| null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00782574
|
Active, not recruiting
| 1 |
2008-11-12
| null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00782574
|
Active, not recruiting
| 1 |
2008-11-12
| null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00782574
|
Active, not recruiting
| 1 |
2008-11-12
| null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00782574
|
Active, not recruiting
| 1 |
2008-11-12
| null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00782574
|
Active, not recruiting
| 1 |
2008-11-12
| null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00782574
|
Active, not recruiting
| 1 |
2008-11-12
| null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03742895
|
Recruiting
| 2 |
2018-12-12
| null | null | null | null |
Phase II+
| 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03742895
|
Recruiting
| 2 |
2018-12-12
| null | null | null | null |
Phase II+
| 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03742895
|
Recruiting
| 2 |
2018-12-12
| null | null | null | null |
Phase II+
| 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03742895
|
Recruiting
| 2 |
2018-12-12
| null | null | null | null |
Phase II+
| 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03742895
|
Recruiting
| 2 |
2018-12-12
| null | null | null | null |
Phase II+
| 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03742895
|
Recruiting
| 2 |
2018-12-12
| null | null | null | null |
Phase II+
| 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03742895
|
Recruiting
| 2 |
2018-12-12
| null | null | null | null |
Phase II+
| 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03742895
|
Recruiting
| 2 |
2018-12-12
| null | null | null | null |
Phase II+
| 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03742895
|
Recruiting
| 2 |
2018-12-12
| null | null | null | null |
Phase II+
| 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00819221
|
Active, not recruiting
| 1 |
2009-01-05
| null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00819221
|
Active, not recruiting
| 1 |
2009-01-05
| null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00819221
|
Active, not recruiting
| 1 |
2009-01-05
| null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00819221
|
Active, not recruiting
| 1 |
2009-01-05
| null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00819221
|
Active, not recruiting
| 1 |
2009-01-05
| null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00819221
|
Active, not recruiting
| 1 |
2009-01-05
| null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00819221
|
Active, not recruiting
| 1 |
2009-01-05
| null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00819221
|
Active, not recruiting
| 1 |
2009-01-05
| null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00819221
|
Active, not recruiting
| 1 |
2009-01-05
| null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00516802
|
Completed
| 1 |
2007-01-01
| null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00516802
|
Completed
| 1 |
2007-01-01
| null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00516802
|
Completed
| 1 |
2007-01-01
| null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00516802
|
Completed
| 1 |
2007-01-01
| null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00516802
|
Completed
| 1 |
2007-01-01
| null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00516802
|
Completed
| 1 |
2007-01-01
| null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00516802
|
Completed
| 1 |
2007-01-01
| null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00516802
|
Completed
| 1 |
2007-01-01
| null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00516802
|
Completed
| 1 |
2007-01-01
| null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01063816
|
Completed
| 1 |
2010-01-01
| null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01063816
|
Completed
| 1 |
2010-01-01
| null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01063816
|
Completed
| 1 |
2010-01-01
| null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01063816
|
Completed
| 1 |
2010-01-01
| null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01063816
|
Completed
| 1 |
2010-01-01
| null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01063816
|
Completed
| 1 |
2010-01-01
| null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01063816
|
Completed
| 1 |
2010-01-01
| null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01063816
|
Completed
| 1 |
2010-01-01
| null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01063816
|
Completed
| 1 |
2010-01-01
| null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03499444
|
Active, not recruiting
| 1 |
2018-02-06
| null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03499444
|
Active, not recruiting
| 1 |
2018-02-06
| null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03499444
|
Active, not recruiting
| 1 |
2018-02-06
| null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03499444
|
Active, not recruiting
| 1 |
2018-02-06
| null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03499444
|
Active, not recruiting
| 1 |
2018-02-06
| null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03499444
|
Active, not recruiting
| 1 |
2018-02-06
| null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03499444
|
Active, not recruiting
| 1 |
2018-02-06
| null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03499444
|
Active, not recruiting
| 1 |
2018-02-06
| null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03499444
|
Active, not recruiting
| 1 |
2018-02-06
| null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00777582
|
Active, not recruiting
| 1 |
2008-10-27
| null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00777582
|
Active, not recruiting
| 1 |
2008-10-27
| null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00777582
|
Active, not recruiting
| 1 |
2008-10-27
| null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00777582
|
Active, not recruiting
| 1 |
2008-10-27
| null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00777582
|
Active, not recruiting
| 1 |
2008-10-27
| null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00777582
|
Active, not recruiting
| 1 |
2008-10-27
| null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00777582
|
Active, not recruiting
| 1 |
2008-10-27
| null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00777582
|
Active, not recruiting
| 1 |
2008-10-27
| null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT00777582
|
Active, not recruiting
| 1 |
2008-10-27
| null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03553108
|
Completed
| 1 |
2018-05-16
| null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03553108
|
Completed
| 1 |
2018-05-16
| null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03553108
|
Completed
| 1 |
2018-05-16
| null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03553108
|
Completed
| 1 |
2018-05-16
| null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03553108
|
Completed
| 1 |
2018-05-16
| null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03553108
|
Completed
| 1 |
2018-05-16
| null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03553108
|
Completed
| 1 |
2018-05-16
| null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03553108
|
Completed
| 1 |
2018-05-16
| null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT03553108
|
Completed
| 1 |
2018-05-16
| null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01921140
|
Active, not recruiting
| 1 |
2013-09-24
| null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01921140
|
Active, not recruiting
| 1 |
2013-09-24
| null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01921140
|
Active, not recruiting
| 1 |
2013-09-24
| null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01921140
|
Active, not recruiting
| 1 |
2013-09-24
| null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01921140
|
Active, not recruiting
| 1 |
2013-09-24
| null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01921140
|
Active, not recruiting
| 1 |
2013-09-24
| null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01921140
|
Active, not recruiting
| 1 |
2013-09-24
| null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01921140
|
Active, not recruiting
| 1 |
2013-09-24
| null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
chembl
|
known_drug
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT01921140
|
Active, not recruiting
| 1 |
2013-09-24
| null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
expression_atlas
|
rna_expression
| 413,311 |
ENSG00000041880
|
EFO_0000616
|
NCT04171700
|
Recruiting
| 2 |
2019-11-21
| null | null | null | null |
Phase II+
| 463,856,468,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 4 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from1to10
|
europepmc
|
literature
| 413,311 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.